Thomas J. Cradick

机构：Atara Biotherapeutics (United States) · ORCID：0000-0002-8489-8318

发表论文 43 篇 · 总被引 9088 次 · h-index 22

代表论文

• CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences (2014 · Nucleic Acids Research · 被引 655)
• Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection (2014 · Proceedings of the National Academy of Sciences · 被引 319)
• Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome (2015 · Molecular Therapy · 被引 259)
• The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells (2016 · Molecular Therapy · 被引 253)
• TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity (2014 · Nucleic Acids Research · 被引 191)
• Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus (2018 · Blood · 被引 188)